Lakefront Biotherapeutics NV 2021 AR2
The report highlights Galapagos' transition to becoming a fully integrated, independent European biopharma company in 2021, marked by the successful commercial roll-out of Jyseleca (filgotinib) for rheumatoid arthritis and ulcerative colitis in Europe. Despite pipeline setbacks, including the discontinuation of ziritaxestat, the company advanced its inflammation franchise with positive Phase 1b results for TYK2 inhibitor GLPG3667 and SIK2/3 inhibitor GLPG3970. Galapagos also initiated a company-wide Corporate Social Responsibility strategy, aligning its operations with the UN Sustainable Development Goals. Financially, the company maintained a strong balance sheet with 4.7 billion euros in current financial investments and cash, while implementing a 150 million euro cost-savings program.
Company: Lakefront Biotherapeutics NV
Sector: Professional & technical services
Country: Belgium
Year: 2021
Type: AR2
Pages: 284
Back to company
Lakefront Biotherapeutics NV
Annual Report
The report highlights Galapagos' transition to becoming a fully integrated, independent European biopharma company in 2021, marked by the successful commercial roll-out of Jyseleca (filgotinib) for rheumatoid arthritis and ulcerative colitis in Europe. Despite pipeline setbacks, including the discontinuation of ziritaxestat, the company advanced its inflammation franchise with positive Phase 1b results for TYK2 inhibitor GLPG3667 and SIK2/3 inhibitor GLPG3970. Galapagos also initiated a company-wide Corporate Social Responsibility strategy, aligning its operations with the UN Sustainable Development Goals. Financially, the company maintained a strong balance sheet with 4.7 billion euros in current financial investments and cash, while implementing a 150 million euro cost-savings program.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees